Tags

Type your tag names separated by a space and hit enter

Prognostic role of FEV1 for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.
Clin Transplant 2015; 29(12):1133-9CT

Abstract

BACKGROUND

Bronchiolitis obliterans syndrome (BOS) can occur after hematopoietic stem cell transplantation (HSCT) and is associated with significant mortality. We investigated the role of forced expiratory volume in one s (FEV1) as a prognostic marker in BOS after HSCT.

METHODS

Among all patients who underwent HSCT between December 1993 and November 2013 at a tertiary center in South Korea, 1187 patients were enrolled. Patient medical records were retrospectively analyzed to evaluate the prognostic factors associated with survival in these cases.

RESULTS

During a median follow-up period of 30.7 months after HSCT, 82 patients (6.9%) were diagnosed with BOS. The mean FEV1 of the BOS patients was 34.7% of predicted, and the mean FEV1 of 31 of these patients (37.8%) was <30% of predicted. The estimated overall survival rate for BOS patients excluding three patients who received lung transplantation was 74% at three yr from BOS diagnosis. Multivariate analysis showed that diagnosis of BOS within six months and FEV1 < 30% of predicted at the time of BOS diagnosis were associated with shorter survival.

CONCLUSIONS

An FEV1 < 30% of predicted at the time of diagnosis is significantly associated with an increased risk of death in patients with BOS after HSCT.

Authors+Show Affiliations

Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.Division of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.Division of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.Division of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.Division of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.Division of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26383085

Citation

Ahn, Jee Hwan, et al. "Prognostic Role of FEV1 for Survival in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation." Clinical Transplantation, vol. 29, no. 12, 2015, pp. 1133-9.
Ahn JH, Jo KW, Song JW, et al. Prognostic role of FEV1 for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. Clin Transplant. 2015;29(12):1133-9.
Ahn, J. H., Jo, K. W., Song, J. W., Shim, T. S., Lee, S. W., Lee, J. S., ... Lee, K. H. (2015). Prognostic role of FEV1 for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. Clinical Transplantation, 29(12), pp. 1133-9. doi:10.1111/ctr.12638.
Ahn JH, et al. Prognostic Role of FEV1 for Survival in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation. Clin Transplant. 2015;29(12):1133-9. PubMed PMID: 26383085.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognostic role of FEV1 for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. AU - Ahn,Jee Hwan, AU - Jo,Kyung-Wook, AU - Song,Jin Woo, AU - Shim,Tae Sun, AU - Lee,Sei Won, AU - Lee,Jae Seung, AU - Kim,Dae-Young, AU - Lee,Je-Hwan, AU - Lee,Jung-Hee, AU - Choi,Yunsuk, AU - Lee,Kyoo-Hyung, Y1 - 2015/10/30/ PY - 2015/09/14/accepted PY - 2015/9/19/entrez PY - 2015/9/19/pubmed PY - 2016/11/1/medline KW - FEV 1 KW - bronchiolitis obliterans syndrome KW - hematopoietic stem cell transplantation KW - prognosis KW - survival SP - 1133 EP - 9 JF - Clinical transplantation JO - Clin Transplant VL - 29 IS - 12 N2 - BACKGROUND: Bronchiolitis obliterans syndrome (BOS) can occur after hematopoietic stem cell transplantation (HSCT) and is associated with significant mortality. We investigated the role of forced expiratory volume in one s (FEV1) as a prognostic marker in BOS after HSCT. METHODS: Among all patients who underwent HSCT between December 1993 and November 2013 at a tertiary center in South Korea, 1187 patients were enrolled. Patient medical records were retrospectively analyzed to evaluate the prognostic factors associated with survival in these cases. RESULTS: During a median follow-up period of 30.7 months after HSCT, 82 patients (6.9%) were diagnosed with BOS. The mean FEV1 of the BOS patients was 34.7% of predicted, and the mean FEV1 of 31 of these patients (37.8%) was <30% of predicted. The estimated overall survival rate for BOS patients excluding three patients who received lung transplantation was 74% at three yr from BOS diagnosis. Multivariate analysis showed that diagnosis of BOS within six months and FEV1 < 30% of predicted at the time of BOS diagnosis were associated with shorter survival. CONCLUSIONS: An FEV1 < 30% of predicted at the time of diagnosis is significantly associated with an increased risk of death in patients with BOS after HSCT. SN - 1399-0012 UR - https://www.unboundmedicine.com/medline/citation/26383085/Prognostic_role_of_FEV1_for_survival_in_bronchiolitis_obliterans_syndrome_after_allogeneic_hematopoietic_stem_cell_transplantation_ L2 - https://doi.org/10.1111/ctr.12638 DB - PRIME DP - Unbound Medicine ER -